Abstract
One hundred years have passed since the discovery of insulin—an achievement that transformed diabetes from a fatal illness into a manageable chronic condition. The decades since that momentous achievement have brought ever more rapid innovation and advancement in diabetes research and clinical care. To celebrate the important work of the past century and help to chart a course for its continuation into the next, the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases recently held a joint international symposium, bringing together a cohort of researchers with diverse interests and backgrounds from both countries and beyond to discuss their collective quest to better understand the heterogeneity of diabetes and thus gain insights to inform new directions in diabetes treatment and prevention. This article summarizes the proceedings of that symposium, which spanned cutting-edge research into various aspects of islet biology, the heterogeneity of diabetic phenotypes, and the current state of and future prospects for precision medicine in diabetes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 697-713 |
| Number of pages | 17 |
| Journal | Canadian Journal of Diabetes |
| Volume | 45 |
| Issue number | 8 |
| DOIs | |
| State | Published - Dec 2021 |
Bibliographical note
Funding Information:Editorial services for this article were provided by Debbie Kendall of Kendall Editorial in Richmond, VA, and funded by the American Diabetes Association .
Funding Information:
Editorial services for this article were provided by Debbie Kendall of Kendall Editorial in Richmond, VA, and funded by the American Diabetes Association. The authors thank the following planning committee members, moderators, and speakers for the ?Heterogeneity of Diabetes: ?-Cells, Phenotypes, and Precision Medicine? live webinar symposium held 2?3 June 2021 for their contributions to the event and to this article. Planning Committee. Co-chairs: Norman Rosenblum and William Cefalu. Members: Dana K. Andersen, Guillermo Arreaza-Rub?n, Christine Dhara, Stephen P. James, Mary-Jo Makarchuk, Christopher L. Pin, Sheryl Sato, Bruce Verchere, and Minna Woo. Moderators. Session 1: Alvin Powers, Jennifer Estall, Corrine Hoesli, Jeffrey Millman, Amelia Linnemann, and James Johnson. Session 2: Christopher L. Pin, Meredith Hawkins, Minna Woo, and Anna Gloyn. Session 3: William Cefalu and Norman Rosenblum. Speakers. Session 1: Mark O. Huising, Richard K.P. Benninger, Joana Alma?a, Rebecca L. Hull-Meichle, Patrick MacDonald, Francis Lynn, Juan Melero-Martin, Eiji Yoshihara, Cherie Stabler, Maike Sander, Carmella Evans-Molina, Feyza Engin, Peter Thompson, and Anath Shalev. Session 2: Maria J. Redondo, Kristen Nadeau, Melena Bellin, Miriam S. Udler, John Dennis, Satya Dash, Wenyu Zhou, Michael Snyder, and Gillian Booth. Session 3: Atul Butte and Jose Florez. Additionally, the authors acknowledge and appreciate Christine Dhara at CIHR and Leeanna Arrowchis at NIDDK for their contributions to the symposium. The Planning Committee wishes to thank the staff of The Scientific Consulting Group, Inc. for their coordination of the meeting logistics and technical services enabling this symposium commemorating the 100th anniversary of the discovery of insulin. Funding. The symposium and its proceedings were co-funded/co-sponsored by the NIDDK and CIHR. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. N.D.R. and W.T.C. wrote the introduction and conclusion. D.K.A. wrote the summary of the symposium's third session, G.A.-R. S.S. and C.B.V. wrote the summary of the first session, and C.L.P. and M.W. wrote the summary of the second session. All of the authors reviewed and edited the final manuscript. N.D.R. and W.T.C. are the guarantors of this work.
Publisher Copyright:
© 2021
